WEIZMANN TECHNOLOGY PARK, Israel—Herbamed Ltd. appoints New Products Plus (NPP), Salt Lake City, as its exclusive agent for Ultrasome™ CoQ10 (coenzyme Q10) in the Western United States. Ultrasome CoQ10 is available in a stable powder that can be easily used in capsules and tablets.
"We are extremely happy to join forces with the NPP team," said David Hart, business development and marketing manager at Herbamed. "This is our first foray to bring innovative Ultrasome CoQ10 to the U.S. market."
Ultrasome is a liposomal-type patent-protected formulation of CoQ10 designed to increase the bioavailability of CoQ10 by combining ubiquinone with a dual layer of phospholipids to create a small droplet. The liposome thereby protects the CoQ10 and delivers it further into the intestines for better absorption. Clinical studies support its efficacy; one trial in geriatric patients found Ultrasome had three times the bioavailability compared to standard CoQ10. A similar trial in younger adults realized a 10-fold increase in bioavailability.
"Ultrasome gives us an entry into the CoQ10 market," said Greg Flinn, president of NPP. "We are happy to team with a company like Herbamed, who makes a significant investment in science and intellectual property behind their products."